Drugsampling.com, a computer controlled system that monitors the distribution of drug samples, is being tested in Boston's Lahey Clinic.
Drugsampling.com, a computer controlled system that monitors the distribution of drug samples, is being tested in Boston's Lahey Clinic.
"Insufficient control [of drug samples] can endanger patients and staff and clearly violates accreditation standards and regulatory statutes," said Ernie Anderson, director of pharmacy at Lahey Clinic. "It also contributes to higher drug costs and makes it difficult for pharmaceutical companies to obtain credible sampling data."
The Drugsampling.com system, which was developed by the Lahey Clinic with the help of ADDS Inc., North Billerica, MA, includes computer-controlled dispensing cabinets that hold a wide range of samples. The cabinets can only be opened by authorized medical staff who are identified through fingerprint-recognition technology.
Once opened, the cabinet contains a touch screen computer that enables physicians to input their name, patient name and drug to be sampled. The system then prints out educational material and labels for the patient in accordance with all Joint Commission on Accreditation of Healthcare Organizations standards while documenting transactions completely.
Currently, Lahey Clinic has the new systems working with 12 clinics and plans to add 12 more before expanding to 44 regional clinics. PR
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.